Previous 10 | Next 10 |
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
IGM Biosciences Inc. (IGMS) is expected to report $-1.25 for Q3 2023
2023-10-20 17:24:19 ET Gainers: Day One Biopharmaceuticals ( DAWN ) +6% . ContextLogic ( WISH ) +5% . Vital Farms ( VITL ) +5% . Verona Pharma ( VRNA ) +4% . GoPro ( GPRO ) +3% . Losers: IGM Biosciences ( IG...
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 pa...
2023-10-04 11:11:30 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences: High OpEx And Underwhelming Monotherapy Data Warrant Caution IGM Bioscience announces departure of chairman Michael Loberg ...
2023-10-03 16:38:40 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences: High OpEx And Underwhelming Monotherapy Data Warrant Caution Seeking Alpha’s Quant Rating on IGM Biosciences Histor...
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chai...
2023-10-01 06:44:10 ET Summary IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company. IGM-2323, now called imvotamab, has shifted i...
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside c...
2023-08-03 17:41:02 ET IGM Biosciences press release ( NASDAQ: IGMS ): Q2 GAAP EPS of -$1.43 beats by $0.01 . Revenue of $0.45M (+21.6% Y/Y) misses by $0.34M . For further details see: IGM Biosciences GAAP EPS of -$1.43 beats by $0.01, revenue of $0.45M m...
News, Short Squeeze, Breakout and More Instantly...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 33.8% to $0.0788 on volume of 1,221,538,672 shares Akoustis Technologies Inc. (AKTS) rose 128.8% to $0.3151 on volume of 536,119,838 shares Crown Electrokinetics Corp. (CRKN) rose 3.1% t...